CONCORD, Calif.--(BUSINESS WIRE)--Feb. 4, 2008--Cerus Corporation (NASDAQ:CERS) announced today that company management will present at the 10th Annual BIO CEO & Investor Conference in New York City. Cerus' presentation will begin at 3:30 p.m. EST on Monday, February 11, 2008. To access the live webcast, please log on to the company's website at www.cerus.com. An archived presentation will be available on the website until February 18, 2008.

ABOUT CERUS

Cerus Corporation is a biopharmaceutical company focused on the development and commercialization of the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The company currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, the Middle East and Russia. The company is in early clinical development of the INTERCEPT Blood System for red blood cells in the United States.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

CONTACT: Cerus Corporation
William J. Dawson, 925-288-6053
VP, Finance & CFO
or
Vida Communication (On behalf of CERUS)
Stephanie Diaz, 415-675-7401

SOURCE: Cerus Corporation